SGHT · XBRL financial data

Sight Sciences financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SGHT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	48,956	71,331	81,056	79,866	77,363
Cost of goods and services sold	8,610	12,361	11,881	11,581	10,697
Gross profit	40,346	58,970	69,175	68,285	66,666
Research and development	15,634	22,859	17,556	17,991	14,606
Selling, general and administrative	76,190	120,065	108,893	100,826	89,159
Total operating expenses	91,824	142,924	126,449	118,817	103,765
Operating income (loss)	(51,478)	(83,954)	(57,274)	(50,532)	(37,099)
Interest expense	4,366	4,466	5,408	4,662	5,142
Other income (expense)	(6,928)	2,225	7,245	(32)	(148)
Income tax expense (benefit)	188	47	110	236	10
Net income (loss)	(62,960)	(86,242)	(55,547)	(51,507)	(38,426)
Earnings per share, basic USD per share	(2.36)	(1.80)	(1.14)	(1.03)	(0.74)
Earnings per share, diluted USD per share	(2.36)	(1.80)	(1.14)	(1.03)	(0.74)
Weighted average shares, basic thousands of shares	26,734	47,849	48,629	50,134	52,149
Weighted average shares, diluted thousands of shares	26,734	47,849	48,629	50,134	52,149

Fiscal years (SGHT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	260,687	185,000	138,129	120,357	91,965
Accounts receivable	8,709	15,148	14,289	10,786	9,745
Inventory	3,475	6,114	7,849	6,325	7,767
Prepaid and other current assets	4,164	3,415	2,604	2,306	3,257
Total current assets	277,035	209,677	162,871	139,774	112,734
Property and equipment, net	1,454	1,571	1,640	1,580	1,610
Right-of-use asset	1,495	1,614	1,458	935	438
Total assets	280,186	213,073	166,651	142,839	115,300
Accounts payable	3,351	2,688	1,731	1,691	1,343
Accrued liabilities	2,726	5,307	1,639	2,113	2,140
Current portion of long-term debt	0	0	2,219	0	0
Total current liabilities	13,504	17,817	12,252	15,468	11,027
Long-term debt	32,656	33,313	31,708	39,356	40,300
Lease liability, non-current	1,040	635	914	473	0
Total liabilities	48,079	52,997	46,436	55,316	51,358
Accumulated deficit	(153,001)	(239,243)	(294,790)	(346,297)	(384,723)
Total stockholders' equity	232,107	160,076	120,215	87,523	63,942
Total liabilities and equity	280,186	213,073	166,651	142,839	115,300
Common shares outstanding (cover page) thousands of shares	47,587	48,420	49,553	51,333	54,006

Fiscal years (SGHT's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(62,960)	(86,242)	(55,547)	(51,507)	(38,426)
Stock-based compensation	5,083	12,963	14,581	17,077	13,054
Depreciation and amortization	—	—	614	712	487
Net cash from operating activities	(52,540)	(75,965)	(47,184)	(22,351)	(29,694)
Purchases of property and equipment	813	970	791	385	224
Net cash from investing activities	(813)	(970)	(791)	(385)	(224)
Net cash from financing activities	252,529	1,248	1,104	4,964	1,791
Net change in cash	199,176	(75,687)	(46,871)	(17,772)	(28,127)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Sight Sciences	77,402	24,923	(2,402)*	55.6M	15.2 quarters	Q3 FY26 10-QSep 30, 2026
Profound Medical	38,271	2,483	(11,338)*	36.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Stereotaxis	10,491	7,670	(3,675)*	100.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
SkinHealth Systems	206,074	72,113	2,671*	130.1M	—	Q2 FY26 10-QJun 30, 2026
Sanara MedTech	15,421	28,137	2,038*	9.2M	—	Q2 FY26 10-QJun 30, 2026
Anika Therapeutics	38,412	32,610	(684)*	13.4M	56.2 quarters	Q2 FY26 10-QJun 30, 2026
Utah Medical Products	87,528	8,529	1,383*	3.2M	—	Q2 FY26 10-QJun 30, 2026
AVITA Medical	9,139	21,702	(3,496)*	30.9M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Lakeland Industries	17,901	50,139	(404)*	9.9M	—	Q2 FY27 10-QJul 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.